The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.
To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
54
60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Jilin cancer hospital
Changchun, Jilin, China
RECRUITINGLimiting Toxicity (DLT )in the irinotecan
Time frame: up to 18 weeks
Maximum Tolerated Dose(MTD)in the irinotecan
Time frame: up to 18weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.